415 related articles for article (PubMed ID: 32527134)
1. Effect on survival of local treatment in patients with low prostate-specific antigen, high Gleason score prostate cancer: a population-based propensity score-matched analysis.
Liu S; Wang XY; Huang TB; Niu Q; Yao K; Song X; Zhou SY; Chen Z; Zhou GC
Ann Palliat Med; 2020 Jul; 9(4):1708-1717. PubMed ID: 32527134
[TBL] [Abstract][Full Text] [Related]
2. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
3. Elderly patients aged ≥ 75 years with locally advanced prostate cancer may benefit from local treatment: a population-based propensity score-adjusted analysis.
Sheng W; Kirschner-Hermanns R; Zhang H
World J Urol; 2019 Feb; 37(2):317-325. PubMed ID: 29951790
[TBL] [Abstract][Full Text] [Related]
4. Overall survival and cancer-specific survival were improved in local treatment of metastatic prostate cancer.
Miao Q; Wei Z; Liu C; Ye Y; Cheng G; Song Z; Chen K; Zhang Y; Chen J; Yue C; Ruan H; Zhang X
Front Oncol; 2023; 13():1130680. PubMed ID: 37207146
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis.
Bandini M; Pompe RS; Marchioni M; Tian Z; Gandaglia G; Fossati N; Tilki D; Graefen M; Montorsi F; Shariat SF; Briganti A; Saad F; Karakiewicz PI
World J Urol; 2018 Jan; 36(1):7-13. PubMed ID: 29063268
[TBL] [Abstract][Full Text] [Related]
6. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages.
Pompe RS; Tilki D; Preisser F; Leyh-Bannurah SR; Bandini M; Marchioni M; Gild P; Tian Z; Fossati N; Cindolo L; Shariat SF; Huland H; Graefen M; Briganti A; Karakiewicz PI
Prostate; 2018 Jul; 78(10):753-757. PubMed ID: 29663462
[TBL] [Abstract][Full Text] [Related]
7. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations.
Leyh-Bannurah SR; Karakiewicz PI; Pompe RS; Preisser F; Zaffuto E; Dell'Oglio P; Briganti A; Nafez O; Fisch M; Steuber T; Graefen M; Budäus L
World J Urol; 2019 Mar; 37(3):469-479. PubMed ID: 29992380
[TBL] [Abstract][Full Text] [Related]
8. Impact of surgical margin status on prostate-cancer-specific mortality.
Chalfin HJ; Dinizo M; Trock BJ; Feng Z; Partin AW; Walsh PC; Humphreys E; Han M
BJU Int; 2012 Dec; 110(11):1684-9. PubMed ID: 22788795
[TBL] [Abstract][Full Text] [Related]
9. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
[TBL] [Abstract][Full Text] [Related]
10. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
11. Primary Gleason grade 4 at the positive margin is associated with metastasis and death among patients with Gleason 7 prostate cancer undergoing radical prostatectomy.
Viers BR; Sukov WR; Gettman MT; Rangel LJ; Bergstralh EJ; Frank I; Tollefson MK; Thompson RH; Boorjian SA; Karnes RJ
Eur Urol; 2014 Dec; 66(6):1116-24. PubMed ID: 25052213
[TBL] [Abstract][Full Text] [Related]
12. Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.
Park JW; Jang WS; Koh DH; Ham WS; Rha KH; Hong SJ; Choi YD
Yonsei Med J; 2018 Jul; 59(5):580-587. PubMed ID: 29869455
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
Löppenberg B; Dalela D; Karabon P; Sood A; Sammon JD; Meyer CP; Sun M; Noldus J; Peabody JO; Trinh QD; Menon M; Abdollah F
Eur Urol; 2017 Jul; 72(1):14-19. PubMed ID: 27174537
[TBL] [Abstract][Full Text] [Related]
14. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcomes for Metastatic Prostate Cancer Patients Treated With Radical Prostatectomy or Radiation Therapy: A SEER-based Study.
Jin K; Qiu S; Jin H; Zheng X; Zhou X; Jin D; Li J; Yang L; Wei Q
Clin Genitourin Cancer; 2020 Dec; 18(6):e705-e722. PubMed ID: 32763123
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes of patients treated with local therapy for nonmetastatic prostate cancer with high prostate-specific antigen concentrations.
Ślusarczyk A; Baboudjian M; Zapała P; Yanagisawa T; Miszczyk M; Chlosta M; Krumpoeck P; Moschini M; Gandaglia G; Ploussard G; Rivas JG; Życzkowski M; Karakiewicz PI; Radziszewski P; Leapman MS; Shariat SF; Rajwa P
Prostate; 2023 Nov; 83(15):1504-1515. PubMed ID: 37545342
[TBL] [Abstract][Full Text] [Related]
17. Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis.
Shao YH; Kim S; Moore DF; Shih W; Lin Y; Stein M; Kim IY; Lu-Yao GL
Eur Urol; 2014 Apr; 65(4):693-700. PubMed ID: 23759328
[TBL] [Abstract][Full Text] [Related]
18. Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5.
Panunzio A; Sorce G; Hoeh B; Hohenhorst L; Tappero S; Nimer N; Rajwa P; Tian Z; Terrone C; Chun FKH; Briganti A; Saad F; Shariat SF; Cerruto MA; Antonelli A; Karakiewicz PI
Prostate; 2023 Feb; 83(3):268-276. PubMed ID: 36336728
[TBL] [Abstract][Full Text] [Related]
19. Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.
Steuber T; Jilg C; Tennstedt P; De Bruycker A; Tilki D; Decaestecker K; Zilli T; Jereczek-Fossa BA; Wetterauer U; Grosu AL; Schultze-Seemann W; Heinzer H; Graefen M; Morlacco A; Karnes RJ; Ost P
Eur Urol Focus; 2019 Nov; 5(6):1007-1013. PubMed ID: 29530632
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of incidental prostate cancer in the United States.
Scheipner L; Incesu RB; Morra S; Baudo A; Assad A; Jannello LMI; Siech C; de Angelis M; Barletta F; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Tilki D; Longo N; Carmignani L; De Cobelli O; Ahyai S; Karakiewicz PI
Prostate Cancer Prostatic Dis; 2023 Oct; ():. PubMed ID: 37872250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
